CEO Amit Etkin states: “We are disheartened by the results from this study as the unmet need in this patient population is immense. While the results are surprising and disappointing, I am proud of our team for conducting a first-of-its-kind precision biomarker-based study in psychiatry. We will move quickly to evaluate the full data set to better understand these findings and incorporate learnings from this large data set across our platform. We remain committed to our mission of helping patients get better faster by bringing precision medicine to psychiatry, and we expect our strong cash balance to support us through multiple near-term clinical milestones across our pipeline.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ANRO:
- Alto Neuroscience falls 47% after announcing ALTO-100 did not meet endpoint
- Alto Neuroscience’s Phase 2b study of ALTO-100 did not meet primary endpoint
- Alto Neuroscience falls -3.8%
- Four new option listings and one option delisting on September 18th
- Alto Neuroscience: No demonstrative efficacy in MDD patients with vortioxetine
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
